WSK-V102C COVID-19 vaccine effectiveness against SARS-CoV-2 JN.1 symptomatic infection among adults 60 years and older: a prospective observational cohort study in Shaanxi Province, China, 2024
Among individuals aged ≥ 60 years, WSK-V102C vaccination provided moderate protection against JN.1 symptomatic infection within 6 months, suggesting that older people can benefit from use of this vaccine.
Authors
- Lance E. Rodewald (ORCID: https://orcid.org/0000-0003-2593-542X)
- Zhixin Feng (ORCID: https://orcid.org/0000-0001-9113-4706)
- Fuzhen Wang (ORCID: https://orcid.org/0000-0002-6784-7711)
- Rong Wang (ORCID: https://orcid.org/0000-0002-2780-0206)
- Zundong Yin (ORCID: https://orcid.org/0000-0002-8901-5326)
- Shaobai Zhang (ORCID: https://orcid.org/0000-0002-3488-3505)
- Siyu Liu (ORCID: https://orcid.org/0000-0002-0966-4589)
- Yajun Li (ORCID: https://orcid.org/0000-0001-8925-9999)
- Qianqian Liu (ORCID: https://orcid.org/0000-0002-7160-8158)
- Xiaoqi Wang (ORCID: https://orcid.org/0000-0001-6225-9307)
- Xiaoxue Liu (ORCID: https://orcid.org/0000-0002-0138-5905)
- Lin Tang
- Chunyan Guo (ORCID: https://orcid.org/0000-0001-7188-2256)
- Yuelei Wang
- Ningpei Bai
- Weijun Hu
Institutions
- Chinese Center For Disease Control and Prevention (CN)
Publication Details
- Journal
- BMC Public Health
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1186/s12889-025-25750-1
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00